Sales 2024 * | 139M 190M | Sales 2025 * | 164M 224M | Capitalization | 524M 717M |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.37M | Net income 2025 * | -11M -15.05M | EV / Sales 2024 * | 3.77 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.19 x |
P/E ratio 2024 * |
-26
x | P/E ratio 2025 * |
-44
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Peregrine Pharmaceuticals
Managers | Title | Age | Since |
---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 20-07-29 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 18-07-31 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 17-11-26 |
Joseph Carleone
CHM | Chairman | 78 | 17-11-26 |
Catherine Mackey
BRD | Director/Board Member | 68 | 19-07-24 |
1st Jan change | Capi. | |
---|---|---|
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |